CD33和SHP-1/PTPN6在阿尔茨海默氏病中的相互作用
Lien Beckers1, Mamunur Rashid1,2,3, Annie J Lee1,4,5
1Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Genes
|September 28, 2024
概括
阿尔茨海默病 (AD) 的遗传风险因素涉及天生的免疫力. 一种特定的CD33变异增加了CD33M表达,改变了其功能和与SHP-1的相互作用,可能导致AD风险.
科学领域:
- 神经免疫学 神经免疫学
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 大规模的遗传研究揭示了先天性免疫细胞在阿尔茨海默病 (AD) 易感性中的作用.
- CD33是一种髓状细胞蛋白,是AD的关键遗传风险因素.
- 在CD33中与AD相关的基因变异改变了其表达和功能,特别是大异型 (CD33M).
研究的目的:
- 研究CD33中AD相关的遗传变异如何影响其与人类微质中的SHP-1相互作用.
- 在AD风险的背景下,探索这些基因型依赖相互作用的功能后果.
主要方法:
- 利用了分子和计算方法.
- 研究了人类微质细胞和微质细胞类细胞的相互作用.
- 分析了涉及CD33,PTPN6 (SHP-1) 和PTPN11 (SHP-2) 的基因相互作用.
主要成果:
- 在微质细胞中显示了CD33和SHP-1之间基因型依赖的相互作用.
- 这种相互作用被认为对与CD33变种相关的AD风险有功能性贡献.
- 发现CD33-PTPN6 (SHP-1) 基因与基因相互作用会影响与AD相关的特征,但CD33-PTPN11 (SHP-2) 相互作用不会.
结论:
- CD33的遗传变异影响其与SHP-1的相互作用,这是潜在的AD易感性潜在的机制.
- CD33和SHP-1之间的相互作用代表了AD病变发生的重要途径.
- 特定的基因相互作用,如CD33-SHP-1,与AD相关,而其他,如CD33-SHP-2,则不相关.
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


